We provide you with 20 years of free, institutional-grade data for GPCR stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of GPCR. Explore the full financial landscape of GPCR stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$227,772
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Coll Crespo Blas | Sale | -8,106 | $7.74 | $62,767 | 2025-09-22 |
| Hall Ashley | Sale | -6,021 | $7.74 | $46,622 | 2025-09-22 |
| Ma Yingli | Sale | -4,470 | $6.84 | $30,560 | 2025-08-20 |
| Lin Xichen | Sale | -12,846 | $6.84 | $87,823 | 2025-08-20 |
| Stevens Raymond C | Grant, award...etc | 89,697 | 2025-07-03 | ||
| Stevens Raymond C | Sale | -28,545 | $7.92 | $225,979 | 2025-07-03 |
| Coll Crespo Blas | Grant, award...etc | 7,992 | 2025-07-03 | ||
| Coll Crespo Blas | Sale | -2,667 | $7.92 | $21,114 | 2025-07-03 |
| Ma Yingli | Grant, award...etc | 24,459 | 2025-07-03 | ||
| Ma Yingli | Sale | -1,824 | $7.92 | $14,440 | 2025-07-03 |
| Lin Xichen | Grant, award...etc | 57,078 | 2025-07-03 | ||
| Lin Xichen | Sale | -6,441 | $7.92 | $50,991 | 2025-07-03 |
| Yoon Jun | Grant, award...etc | 39,606 | 2025-07-03 | ||
| Yoon Jun | Sale | -13,029 | $7.92 | $103,145 | 2025-07-03 |
| Yoon Jun | Grant, award...etc | 170,166 | 2025-03-18 | ||
| Stevens Raymond C | Grant, award...etc | 340,332 | 2025-03-18 | ||
| Ma Yingli | Grant, award...etc | 63,810 | 2025-03-18 | ||
| Lin Xichen | Grant, award...etc | 80,829 | 2025-03-18 | ||
| Hall Ashley | Grant, award...etc | 51,048 | 2025-03-18 | ||
| Coll Crespo Blas | Grant, award...etc | 116,988 | 2025-03-18 | ||
| Hall Ashley | Grant, award...etc | 67,290 | 2024-09-20 | ||
| Coll Crespo Blas | Grant, award...etc | 90,600 | 2024-09-20 | ||
| Coll Crespo Blas | Initial | 2024-09-20 | |||
| Stevens Raymond C | Derivatives Exercise | 150,000 | 2024-06-14 | ||
| Lin Xichen | Derivatives Exercise | 106,200 | 2024-06-05 | ||
| Stevens Raymond C | Grant, award...etc | 134,682 | 2024-03-19 | ||
| Bach Mark Allen | Grant, award...etc | 26,235 | 2024-03-19 | ||
| Lin Xichen | Grant, award...etc | 85,707 | 2024-03-19 | ||
| Ma Yingli | Grant, award...etc | 36,729 | 2024-03-19 | ||
| Yoon Jun | Grant, award...etc | 59,469 | 2024-03-19 | ||
| BVF PARTNERS L P/IL | Initial | 2023-02-13 | |||
| Yoon Jun | Initial | 2023-02-02 | |||
| Stevens Raymond C | Initial | 2023-02-02 |
The information provided in this report about GPCR stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Structure Therapeutics Inc.(NASDAQ:GPCR) 
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 r...
Website: https://structuretx.com
Founded: 2016
IPO Price: $15 (Feb 03, 2023)
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends